Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections

Drugs

Volumn 76, Issue 2, 2016, Pages 231-242

  Scott, Lesley J ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOLOZANE; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; TAZOBACTAM; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ERADICATION THERAPY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MANAGED CARE; PERSONAL EXPERIENCE; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; REVIEW; URINARY TRACT INFECTION; ANALOGS AND DERIVATIVES; INTRAABDOMINAL INFECTIONS; MULTICENTER STUDY (TOPIC); URINARY TRACT INFECTIONS;

ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; INTRAABDOMINAL INFECTIONS; MULTICENTER STUDIES AS TOPIC; PENICILLANIC ACID; URINARY TRACT INFECTIONS;

EID: 84954364353     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-015-0524-5     Document Type: Review

References (57)

1. WHO. The evolving threat of antimicrobial resistance: options for action. 2012. http://www.who.int/. Accessed 18 Sep 2015.
2. Nathwani D, Raman G, Sulham K, et al. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2014;3:32.
3. Center for Disease Prevention and Control. Antibiotic resistance threats in the United States, 2013. 2013. http://www.cdc.gov/drugresistance/. Accessed 18 Sep 2015.
4. Toussaint KA, Gallagher JC. β-lactam/β-lactamase inhibitor combinations: from then to now. Ann Pharmacother. 2015;49(1):86-98.
5. Sucher AJ, Chahine EB, Cogan P, et al. Ceftolozane/tazobactam: a new cephalosporin and β-lactamase inhibitor combination. Ann Pharmacother. 2015;49(9):1046-56.
6. Merck Sharp & Dohme Corp. Zerbaxa™ (ceftolozane and tazobactam) for injection, for intravenous use: US prescribing information. 2015. http://zerbaxa.com/. Accessed 18 Aug 2015.
7. European Medicines Agency. Zerbaxa 1 g/0·5 g powder for concentrate for solution for infusion: summary of product characteristics. 2015. http://www.ema.europa.eu/. Accessed 29 Sep 2015.
8. Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014;74(1):31-51.
9. Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination. Pharmacotherapy. 2015;35(7):701-15.
10. Moya B, Zamorano L, Juan C, et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2010;54(9):3933-7.
11. Bush K, Macalintal C, Rasmussen BA, et al. Kinetic interactions of tazobactam with beta-lactamases from all major structural classes. Antimicrob Agents Chemother. 1993;37(4):851-8.
12. Armstrong ES, Miller B, Popejoy M, et al. Epidemiology and susceptibility of organisms isolated from patients with cIAI: results from ASPECT-cIAI [abstract no. C-774]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.
13. Sader HS, Farrell DJ, Flamm RK, et al. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect. 2014;69(3):266-77.
14. Farrell D, Sader HS, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Enterobacteriaceae isolates from 15 European countries and Israel (2013) [abstract no. P1298 plus poster]. In: 25th European Congress of Clinical Microbiology and Infectious Diseases. 2015.
15. Farrell DJ, Sader HS, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Enterobacteriaceae isolates from 14 European countries and Israel (2012) [abstract no. eP442 plus poster]. In: 24th European Congress of Clinical Microbiology and Infectious Diseases. 2014.
16. McCurdy S, Petersen PJ, Steenbergen J, et al. Ceftolozane/tazobactam activity against gram-negative bacteria causing urinary tract infections in European hospitals (2011-2012): a report from an international antimicrobial surveillance programme [abstract no. eP445 plus poster]. In: 24th European Congress of Clinical Microbiology and Infectious Diseases. 2014.
17. McCurdy S, Petersen PJ, Steenbergen J, et al. Ceftolozane/tazobactam activity against Gram-negative bacteria causing intra-abdominal infections in European hospitals (2011-2012): a report from an international antimicrobial surveillance programme [abstract no. eP446 plus poster]. In: 24th European Congress of Clinical Microbiology and Infectious Diseases. 2014.
18. Zhanel GG, Adam H, Baxter M, et al. In vitro activity of ceftolozane/tazabactam against 5,715 gram-negative and Gram-positive pathogens isolated from patients in Canadian hospitals in 2011 and 2012: CANWARD Surveillance Study [abstract no. E-1689]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.
19. Farrell DJ, Flamm RK, Sader HS, et al. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in US Hospitals (2011-2012). Antimicrob Agents Chemother. 2013;57(12):6305-10.
20. Farrell D, Sader HS, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Pseudomonas aeruginosa isolates from 15 European countries and Israel (2013) [abstract no. P1299 plus poster]. In: 25th European Congress of Clinical Microbiology and Infectious Diseases. 2015.
21. Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother. 2014;58(2):1218-23.
22. Tato M, Garciá-Castillo M, Bofarull AM, et al. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Eneterobacteriaceae recovered in Spanish medical centres: results from the CENIT study. Int J Antimicrob Agents. 2015. doi: 10.1016/j.ijantimicag.2015.07.004.
23. Armstrong ES, Popejoy MW, Cloutier DJ, et al. Analysis of ceftolozane/tazobactam treatment outcomes and in vitro activity using new FDA breakpints in the ASPECT-cUTI and ASPECT-cIAI trials [abstract no. L-1252]. In: 55th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2015.
24. Sutherland CA, Crandon JL, Nicolau DP, et al. Activity of ceftolozane/tazobactam against isolates of Enterobacteriaceae and P. aeruginosa from US hospitals testing non-susceptible to piperacillin/tazobactam [abstract no. C-770]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.
25. Popejoy MW, Armstrong ES, Miller B, et al. Clinical outcomes of ceftolozane/tazobactam treatment of piperacillin/tazobactam and ceftazidime non-susceptible pathogens from two phase 3 trials and asscoiated in vitro activity [abstract no. P1833 plus poster]. In: Infectious Diseases Week. 2015.
26. Takeda S, Nakai T, Wakai Y, et al. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2007;51(3):826-30.
27. Andes D, Alex L. In vivo pharmacodynamics of ceftolozane against Streptococcus pneumoniae and Pseudomonas aeruginosa across a broad range of MICs in a neutropenic murine thigh infection model [abstract no. P1735]. In: 24th European Congress of Clinical Microbiology and Infectious Diseases. 2014.
28. Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother. 2013;57(4):1577-82.
29. Bulik CC, Tessier PR, Keel RA, et al. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrob Agents Chemother. 2012;56(1):544-9.
30. Moya B, Beceiro A, Cabot G, et al. Pan β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother. 2012;56(9):4771-8.
31. Takeda S, Ishii Y, Hatano K, et al. Stability of FR264205 against AmpC beta-lactamase of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2007;30(5):443-5.
32. Cabot G, Bruchmann S, Mulet X, et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother. 2014;58(6):3091-9.
33. Riera E, Macia MD, Mena A, et al. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. J Antimicrob Chemother. 2010;65(7):1399-404.
34. VanScoy B, Mendes RE, Castanheira M, et al. Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model. Antimicrob Agents Chemother. 2014;58(10):6024-31.
35. VanScoy B, Mendes RE, Castanheira M, et al. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother. 2013;57(9):4134-8.
36. Lepak AJ, Reda A, Marchillo K, et al. Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on ceftolozane in vivo pharmacokinetic/pharmacodynamic target. Antimicrob Agents Chemother. 2014;58(10):6311-4.
37. VanScoy B, Mendes RE, Nicasio AM, et al. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother. 2013;57(6):2809-14.
38. Rubino CM, Bhavnani JN, Steenbergen J, et al. Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses supporting the selection of in vitro susceptibility test interpretive criteria for ceftolozane/tazobactam (TOL/TAZ) against Enterobacteriaceae [abstract no. A-1347]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.
39. VanScoy B, Mendes RE, McCauley J, et al. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother. 2013;57(12):5924-30.
40. Bowker KE, Noel AR, Tomaselli SG, et al. Pharmacodynamics of ceftolozane/tazobactam against P. aeruginosa (PSA) studied in an in vitro pharmacokinetic model of infection [abstract no. A-1182]. In: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2014.
41. Miller B, Hershberger E, Benziger D, et al. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects folllowing single and multiple ascending doses. Antimicrob Agents Chemother. 2012;56(6):3086-91.
42. Chandorkar G, Xiao A, Mouksassi MS, et al. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. J Clin Pharmacol. 2015;55(2):230-9.
43. Ge Y, Whitehouse MJ, Friedland I, et al. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob Agents Chemother. 2010;54(8):3427-31.
44. Chandorkar G, Huntington JA, Gotfried MH, et al. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother. 2012;67(10):2463-9.
45. Wooley M, Miller B, Krishna G, et al. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam. Antimicrob Agents Chemother. 2014;58(4):2249-55.
46. Wooley M, Bernardo P, Miller B, et al. Evaluation of the potential for drug-drug interactions between ceftolozane/tazobactam and drugs metabolised by CYP1A2 or CYP3A4 or transported by OAT1 and OAT3 [abstract no. eP450 plus poster]. In: 24th European Congress of Clinical Microbiology and Infectious Diseases. 2014.
47. Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60(10):1462-71.
48. Lucasti C, Hershberger E, Miller B, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58(9):5350-7.
49. Miller B, Popejoy MW, Bernardo P, et al. Ceftolozane/tazobactam plus metronidazole for the treatment of complicated intra-abdominal infection in obese and non-obese hospitalized patients: results from a randomized controlled phase 3 study [abstract no. P1296 plus poster]. In: 25th European Congress of Clinical Microbiology and Infectious Diseases. 2015.
50. Palchak M, Popejoy MW, Miller B, et al. Outcomes of ceftolozane/tazobactam in patients with moderate renal impairment in two phase 3 trials for the treatment of complicated intra-abdominal infections and complicated urinary tract infections [poster no. 901]. In: Infectious Diseases Week. 2015.
51. Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385(9981):1949-56.
52. Solomkin J, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infections in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:133-64.
53. Sartelli M, Viale P, Catena F, et al. WSES guidelines for the management of intra-abdominal infections. World J Emerg Surg. 2013;2013(8):3.
54. Mazzulli T. Diagnosis and management of simple and complicated urinary tract infections (UTIs). Can J Urol. 2012;19(Suppl 1):42-8.
55. European Association of Urology. Guidelines on urological infections. 2015. http://uroweb.org/wp-content/uploads/19-Urological-infections-LR2.pdf. Accessed 21 Oct 2015.
56. Stichting Werkgroep Antibioticabeleid. SWAB guidelines complicated urinary tract infections 2013. 2013. http://www.swab.nl. Accessed 18 Sep 2015.
57. Actavis Inc. Avycaz (ceftazidime and avibactam) for injection, for intravenous use: US prescribing information. 2015. http://pi.actavis.com/. Accessed 11 Nov 2015.